Ocuvex Therapeutics Acquires Visiox Pharmaceuticals

Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals.

Terms of the deal were not disclosed.

Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 receptor agonist for ocular hypertension and open-angle glaucoma. It received FDA approval in September 2022. Last year, Visiox entered into a definitive agreement with Santen Pharmaceutical to license Omlonti. Also included in the deal are Visiox's PDP-716 (brimonidine 0.35%) a once-daily product for ocular hypertension and open angle glaucoma; and SDN-037 (difluprednate 0.04%), a twice daily topical difluprednate for post-surgical inflammation and pain. 

The products will be integrated into Ocuvex's offerings. This move is expected to accelerate the commercialization of these therapeutics, Visiox stated in a news release.

"The combination of Visiox and Ocuvex makes for a perfect match," Ryan S. Bleeks, Chief Executive Officer of Visiox Pharmaceuticals, said in the news release. "We have reached significant milestones with our products, and Ocuvex is in a great position to take these advancements forward, bring them to market faster, and emerge as a future leader in eye care."

Following the merger, the company will operate under the Ocuvex name.